Literature DB >> 19373855

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

Tim Forshew1, Ruth G Tatevossian, Andrew R J Lawson, Jing Ma, Geoff Neale, Babatunji W Ogunkolade, Tania A Jones, Johan Aarum, James Dalton, Simon Bailey, Tracy Chaplin, Rowena L Carter, Amar Gajjar, Alberto Broniscer, Bryan D Young, David W Ellison, Denise Sheer.   

Abstract

We report genetic aberrations that activate the ERK/MAP kinase pathway in 100% of posterior fossa pilocytic astrocytomas, with a high frequency of gene fusions between KIAA1549 and BRAF among these tumours. These fusions were identified from analysis of focal copy number gains at 7q34, detected using Affymetrix 250K and 6.0 SNP arrays. PCR and sequencing confirmed the presence of five KIAA1549-BRAF fusion variants, along with a single fusion between SRGAP3 and RAF1. The resulting fusion genes lack the auto-inhibitory domains of BRAF and RAF1, which are replaced in-frame by the beginning of KIAA1549 and SRGAP3, respectively, conferring constitutive kinase activity. An activating mutation of KRAS was identified in the single pilocytic astrocytoma without a BRAF or RAF1 fusion. Further fusions and activating mutations in BRAF were identified in 28% of grade II astrocytomas, highlighting the importance of the ERK/MAP kinase pathway in the development of paediatric low-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19373855     DOI: 10.1002/path.2558

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  118 in total

Review 1.  Molecular insights into pediatric brain tumors have the potential to transform therapy.

Authors:  Amar Gajjar; Stefan M Pfister; Michael D Taylor; Richard J Gilbertson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.

Authors:  Eric H Raabe; Kah Suan Lim; Julia M Kim; Alan Meeker; Xing-Gang Mao; Guido Nikkhah; Jarek Maciaczyk; Ulf Kahlert; Deepali Jain; Eli Bar; Kenneth J Cohen; Charles G Eberhart
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

3.  Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.

Authors:  Barbara S Paugh; Alberto Broniscer; Chunxu Qu; Claudia P Miller; Junyuan Zhang; Ruth G Tatevossian; James M Olson; J Russell Geyer; Susan N Chi; Nasjla Saba da Silva; Arzu Onar-Thomas; Justin N Baker; Amar Gajjar; David W Ellison; Suzanne J Baker
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

4.  Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome.

Authors:  Jeffrey C Murray; David J Donahue; Saleem I Malik; Yvette B Dzurik; Emily Z Braly; Margaret J Dougherty; Katherine W Eaton; Jaclyn A Biegel
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

5.  The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.

Authors:  AeRang Kim; Cindy McCully; Rafael Cruz; Diane E Cole; Elizabeth Fox; Frank M Balis; Brigitte C Widemann
Journal:  Invest New Drugs       Date:  2010-11-12       Impact factor: 3.850

Review 6.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

7.  Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.

Authors:  Jae Kyung Myung; Hwajin Cho; Chul-Kee Park; Seung-Ki Kim; Se-Hoon Lee; Sung-Hye Park
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 8.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

Review 9.  Molecular markers in pediatric neuro-oncology.

Authors:  Koichi Ichimura; Ryo Nishikawa; Masao Matsutani
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

10.  Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma.

Authors:  Valerie N Barton; Andrew M Donson; Diane K Birks; Bette K Kleinschmidt-DeMasters; Michael H Handler; Nicholas K Foreman; Sarah Z Rush
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.